Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
From Pfizer Inc.
Via Business Wire
Tickers PFE
Cyrus Taraporevala Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Declares Third-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces New Chief Strategy and Innovation Officer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports First-Quarter 2024 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Tickers GMAB PFE
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.